MAP Kinase Kinase 1
-
Subject Areas on Research
- A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development.
- Activation of the 9E3/cCAF chemokine by phorbol esters occurs via multiple signal transduction pathways that converge to MEK1/ERK2 and activate the Elk1 transcription factor.
- Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms.
- Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
- Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
- Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease.
- Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways.
- Feedback regulation of beta-arrestin1 function by extracellular signal-regulated kinases.
- Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma.
- Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
- Ligation of the alpha2M* signaling receptor regulates synthesis of cytosolic phospholipase A2.
- MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.
- MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
- Negative regulation of mTOR activation by diacylglycerol kinases.
- Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity.
- Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.
- UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
- Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.